BRITTANY HARE's Outputs (9)

Rates of medical or surgical treatment for women with heavy menstrual bleeding: the ECLIPSE trial 10-year observational follow-up study (2023)
Journal Article
Kai, J., Dutton, B., Vinogradova, Y., Hilken, N., Gupta, J., & Daniels, J. (2023). Rates of medical or surgical treatment for women with heavy menstrual bleeding: the ECLIPSE trial 10-year observational follow-up study. Health Technology Assessment, 27(17), https://doi.org/10.3310/jhsw0174

Background: Heavy menstrual bleeding is a common problem that can significantly affect women’s lives until menopause. There is a lack of evidence on longer-term outcomes after seeking health care and treatment for heavy menstrual bleeding. Objectives... Read More about Rates of medical or surgical treatment for women with heavy menstrual bleeding: the ECLIPSE trial 10-year observational follow-up study.

Medical treatment for heavy menstrual bleeding in primary care: 10-year data from the ECLIPSE trial (2022)
Journal Article
Kai, J., Dutton, B., Vinogradova, Y., Hilken, N., Gupta, J., & Daniels, J. (2022). Medical treatment for heavy menstrual bleeding in primary care: 10-year data from the ECLIPSE trial. British Journal of General Practice, 72(725), e857-e864. https://doi.org/10.3399/bjgp.2022.0260

Background Heavy menstrual bleeding (HMB) is a common problem that can significantly affect women's lives. There is a lack of evidence on long-term outcomes after seeking treatment. Aim To assess continuation rates of medical treatments and rates of... Read More about Medical treatment for heavy menstrual bleeding in primary care: 10-year data from the ECLIPSE trial.

Comparing the performance of the novel FAMCAT algorithms and established case-finding criteria for familial hypercholesterolaemia in primary care (2021)
Journal Article
Qureshi, N., Akyea, R. K., Dutton, B., Leonardi-Bee, J., Humphries, S. E., Weng, S., & Kai, J. (2021). Comparing the performance of the novel FAMCAT algorithms and established case-finding criteria for familial hypercholesterolaemia in primary care. Open Heart, 8(2), Article e001752. https://doi.org/10.1136/openhrt-2021-001752

Objective Familial hypercholesterolaemia (FH) is a common inherited disorder causing premature coronary heart disease (CHD) and death. We have developed the novel Familial Hypercholesterolaemia Case Ascertainment Tool (FAMCAT 1) case-finding algorith... Read More about Comparing the performance of the novel FAMCAT algorithms and established case-finding criteria for familial hypercholesterolaemia in primary care.

Case-finding and genetic testing for familial hypercholesterolaemia in primary care (2021)
Journal Article
Qureshi, N., Akyea, R. K., Dutton, B., Leonardi-Bee, J., Humphries, S. E., Weng, S., & Kai, J. (2021). Case-finding and genetic testing for familial hypercholesterolaemia in primary care. Heart, 107(24), 1956-1961. https://doi.org/10.1136/heartjnl-2021-319742

Objective: Familial Hypercholesterolaemia (FH) is a common inherited disorder causing premature heart disease and death. We have developed novel case-finding algorithms (FAMCAT version 1 & 2) for application in primary care, to improve detection of... Read More about Case-finding and genetic testing for familial hypercholesterolaemia in primary care.

Specialist recommendation for chemoprevention medications in patients at familial risk of breast cancer: a cross-sectional survey in England (2020)
Journal Article
Lee, S. I., Curtis, H., Qureshi, S., Dutton, B., & Qureshi, N. (2021). Specialist recommendation for chemoprevention medications in patients at familial risk of breast cancer: a cross-sectional survey in England. Journal of Community Genetics, 12(1), 111–120. https://doi.org/10.1007/s12687-020-00490-4

In England, the National Institute for Health and Care Excellence guideline for familial breast cancer recommends chemoprevention for women at high and moderate familial risk of breast cancer. However, prescribing of chemoprevention has not improved... Read More about Specialist recommendation for chemoprevention medications in patients at familial risk of breast cancer: a cross-sectional survey in England.

Improving primary care identification of familial breast cancer risk using proactive invitation and decision support (2020)
Journal Article
Qureshi, N., Dutton, B., Weng, S., Sheehan, C., Chorley, W., Robertson, J. F., …Kai, J. (2021). Improving primary care identification of familial breast cancer risk using proactive invitation and decision support. Familial Cancer, 20(1), 13-21. https://doi.org/10.1007/s10689-020-00188-z

Family history of breast cancer is a key risk factor, accounting for up to 10% of cancers. We evaluated the proactive assessment of familial breast cancer (FBC) risk in primary care. Eligible women (30 to 60 years) were recruited from eight English g... Read More about Improving primary care identification of familial breast cancer risk using proactive invitation and decision support.

Characteristics predicting recommendation for familial breast cancer referral in a cohort of women from primary care (2020)
Journal Article
Lee, S. I., Kai, J., Qureshi, N., Dutton, B., & Weng, S. (2020). Characteristics predicting recommendation for familial breast cancer referral in a cohort of women from primary care. Journal of Community Genetics, 11, 331–338. https://doi.org/10.1007/s12687-020-00452-w

© 2020, The Author(s). Family history of breast and related cancers can indicate increased breast cancer (BC) risk. In national familial breast cancer (FBC) guidelines, the risk is stratified to guide referral decisions. We aimed to identify characte... Read More about Characteristics predicting recommendation for familial breast cancer referral in a cohort of women from primary care.

Effectiveness of interventions to identify and manage patients with familial cancer risk in primary care: a systematic review (2019)
Journal Article
Ing Lee, S., Patel, M., Dutton, B., Weng, S., Luveta, J., & Qureshi, N. (2019). Effectiveness of interventions to identify and manage patients with familial cancer risk in primary care: a systematic review. Journal of Community Genetics, https://doi.org/10.1007/s12687-019-00419-6

This systematic review evaluated the effectiveness of strategies to identify and manage patients with familial risk of breast, ovarian, colorectal and prostate cancer in primary careto improve clinical outcomes. MEDLINE, EMBASE, CINAHL and Cochrane l... Read More about Effectiveness of interventions to identify and manage patients with familial cancer risk in primary care: a systematic review.

Chlorpromazine versus thiothixene for people with schizophrenia (Protocol) (2017)
Journal Article
Cardosa, D., Wakeham, J., Shaw, P. A., Dutton, B., & Wildman, L. (in press). Chlorpromazine versus thiothixene for people with schizophrenia (Protocol). Cochrane Database of Systematic Reviews, https://doi.org/10.1002/14651858.CD012790

This is a protocol for a Cochrane Review (Intervention).
The objectives are as follows: To review the effects of chlorpromazine compared with thiothixene for people with schizophrenia.